TOKYO, Aug. 16 /PRNewswire/ -- R-Tech Ueno, Ltd., together with Sucampo Pharmaceuticals, Inc. ("Sucampo") and Sucampo AG ("SAG"), has requested arbitration against Takeda Pharmaceutical Co. Ltd. ("Takeda").

TOKYO, July 15 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 15 the completion of the Phase II clinical study on the ophthalmic solution UF-021 (product name Ocuseva (TM)) under development as a therapeutic drug for retinitis pigmentosa (Note 1).

TOKYO, June 10 /PRNewswire/ -- Sucampo Pharmaceuticals, Inc.

TOKYO, May 6 /PRNewswire/ -- The Sanda factory of R-Tech Ueno, Ltd. has received notice from the U.S. Food and Drug Administration (FDA) that its facility has been classified as acceptable for the production of pharmaceuticals by meeting compliance with U.S. cGMP regulations (see the note below).

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2008. These results are expected to be disclosed on Wednesday, November 12, 2008 after the capital markets close.